Report Code: CMI43265

Published Date: March 2024

Pages: 320+

Category: Healthcare

Report Snapshot

CAGR: 8.2%
321.4B
2023
347.8B
2024
707.1B
2033

Source: CMI

Study Period: 2024-2033
Fastest Growing Market: Asia-Pacific
Largest Market: Europe

Major Players

  • Roche Holding AG
  • Novartis International AG
  • Bristol Myers Squibb Company
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Others

Exclusive, in-depth market intelligence can help you increase your Revenue.

Download Sample Pdf

Reports Description

As per the current market research conducted by the CMI Team, the global Personalized Cancer Medicine Market is expected to record a CAGR of 8.2% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 347.8 Billion. By 2033, the valuation is anticipated to reach USD 707.1 Billion.

The personalized cancer medicine market encompasses the integration of genomic analysis, molecular profiling, and targeted therapies to tailor treatment approaches to individual patients based on their unique genetic makeup, tumor characteristics, and clinical parameters.

It involves the development and application of precision oncology strategies, including companion diagnostics, biomarker testing, and immunotherapies, to optimize therapeutic efficacy and minimize treatment-related toxicities.

Key components of this market include pharmaceuticals, diagnostics, informatics, and supportive care services. The overarching goal is to deliver more precise and effective cancer treatments, ultimately improving patient outcomes and transforming the standard of care in oncology.

Personalized Cancer Medicine Market – Significant Growth Factors

The Personalized Cancer Medicine Market presents significant growth opportunities due to several factors:

  • Advancements in Genomic Technologies: Continuous advancements in genomic sequencing technologies, such as next-generation sequencing (NGS), enable comprehensive profiling of cancer genomes, facilitating the identification of specific genetic alterations driving cancer progression and guiding personalized treatment strategies.
  • Rising Cancer Incidence and Awareness: With the increasing prevalence of cancer worldwide and growing awareness of the limitations of traditional treatments, there is a heightened demand for personalized cancer medicine that offers tailored therapeutic approaches based on individual patient characteristics.
  • Expansion of Targeted Therapies: Pharmaceutical companies are investing in the development of targeted cancer therapies that selectively inhibit molecular pathways driving tumor growth, leading to more effective and less toxic treatment options for patients with specific genetic mutations or biomarker profiles.
  • Healthcare Digitization and Big Data Analytics: The integration of digital health technologies and big data analytics facilitates the aggregation, analysis, and interpretation of diverse datasets, including genomic data, clinical records, and real-world evidence, enabling more precise patient stratification, treatment selection, and therapeutic monitoring.
  • Expansion of Immunotherapy: The growing understanding of the immune system’s role in cancer progression has led to the development of immunotherapies, which harness the body’s immune response to target and eliminate cancer cells. Opportunities exist to further refine and personalize immunotherapy approaches based on individual patient immune profiles and tumor characteristics.

Personalized Cancer Medicine Market – Mergers and Acquisitions

The Personalized Cancer Medicine Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Personalized Cancer Medicine Market include:

  • In 2023, 23andMe launched the Simvastatin Medication Insight report, analyzing genetic factors influencing individual responses to simvastatin, a cholesterol-lowering medication. This report, part of their medication insights suite, aims to provide personalized information on medication efficacy and potential side effects based on genetic profiles.
  • In 2022, Roche introduced the AVENIO Edge System, a cutting-edge sequencing platform designed to enhance precision medicine solutions. With its fully automated and integrated capabilities, the system aims to advance sequencing technologies and optimize the delivery of personalized cancer treatments.
  • In 2022, Danaher Corporation collaborated with Duke University to launch its inaugural Danaher Beacon for Gene Therapy Innovation. This initiative, part of the Danaher Beacons program, aims to harness cutting-edge science to advance genomic medicines, precision diagnostics, next-gen biomanufacturing, and data sciences for enhancing human health.

These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Personalized Cancer Medicine Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Personalized Cancer Medicine Market Nifedipine Market Pitavastatin Market
CAGR 8.2% (Approx) CAGR 8.1% (Approx) CAGR 6.5% (Approx)
USD 707.1 Billion by 2033 USD 1,661.5 Million by 2032 USD 910.6 Million by 2032

Personalized Cancer Medicine Market – Significant Threats

The Personalized Cancer Medicine Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

  • High Treatment Costs: The personalized cancer medicine market faces the significant threat of high treatment costs associated with targeted therapies and companion diagnostics. These innovative treatments often come with a hefty price tag, posing challenges to healthcare systems, insurers, and patients, especially in regions with limited access to healthcare resources or inadequate insurance coverage.
  • Regulatory Hurdles and Approval Delays: Stringent regulatory requirements for the approval of personalized cancer therapies and companion diagnostics can present significant hurdles for market players. Lengthy approval processes, stringent validation criteria, and evolving regulatory guidelines may delay market entry and limit patient access to innovative treatments, hindering market growth and innovation.
  • Data Privacy and Security Concerns: The collection, storage, and analysis of vast amounts of patient genomic data raise concerns regarding data privacy, security breaches, and unauthorized access. Instances of data breaches or misuse of sensitive genetic information could erode patient trust, lead to legal repercussions, and impede the adoption of personalized cancer medicine solutions, stifling market growth and innovation.
  • Clinical Utility and Validation Challenges: Despite the promise of personalized cancer medicine, challenges persist in demonstrating the clinical utility and validity of biomarkers, molecular profiling technologies, and targeted therapies. Variability in assay performance, lack of standardized protocols, and discordance in study findings may undermine confidence in personalized treatment approaches, leading to skepticism among clinicians, payers, and patients and impeding market adoption.

Global Personalized Cancer Medicine Market 2024–2033 (By End User)

www.custommarketinsight.com

Category-Wise Insights:

By Type

  • Personalized Medicine Therapeutics: Personalized medicine therapeutics involve tailoring treatment regimens to individual patient characteristics, such as genetic makeup or molecular profile. Trends include the development of targeted therapies and immunotherapies, driven by advancements in genomics, biomarker identification, and precision oncology research.
  • Personalized Medicine Diagnostics: Personalized medicine diagnostics aim to identify biomarkers and molecular signatures to guide treatment selection and predict therapeutic response. Trends include the adoption of next-generation sequencing (NGS), liquid biopsy assays, and companion diagnostics, enabling precise patient stratification and therapeutic decision-making in the personalized cancer medicine market.

By Application

  • Oncology: Personalized cancer medicine in oncology involves tailoring treatments based on patients’ genetic makeup and tumor characteristics. Trends include expanding biomarker testing, targeted therapies, and immunotherapies, improving treatment efficacy and patient outcomes.
  • Infectious Disease: In personalized medicine for infectious diseases, treatments are customized based on pathogens’ genetic profiles and patients’ immune responses. Trends include rapid diagnostics, genotype-guided therapy, and vaccine development for personalized prevention strategies.
  • Neurology or Psychiatry: Personalized medicine in neurology and psychiatry focuses on genetic and molecular factors influencing brain disorders. Trends include pharmacogenomics for drug response prediction, biomarker-based diagnostics, and targeted therapies for conditions like Alzheimer’s and depression.
  • Cardiovascular: In personalized cardiovascular medicine, treatments are tailored based on genetic predispositions, lifestyle factors, and disease risk profiles. Trends include genetic risk assessment, biomarker-guided interventions, and precision therapies for conditions like familial hypercholesterolemia and heart failure.
  • Others: Personalized medicine extends to various medical specialties, including rare diseases, autoimmune disorders, and genetic syndromes. Trends include expanding genetic testing capabilities, patient-centric care models, and regulatory support for innovative therapies targeting specific patient populations.

Global Personalized Cancer Medicine Market 2024–2033 (By Type)

www.custommarketinsight.com

By End User

  • Hospitals: Hospitals serve as crucial hubs for personalized cancer medicine, offering comprehensive diagnostic, treatment, and supportive care services. Trends include the integration of molecular profiling into routine oncology practice, the establishment of multidisciplinary tumor boards, and the adoption of electronic health records for seamless data management and treatment coordination.
  • Clinics: Clinics play a vital role in delivering personalized cancer medicine by providing outpatient care, genetic counselling, and biomarker testing services. Trends include the expansion of point-of-care molecular diagnostics, implementation of telemedicine for remote patient monitoring, and adoption of patient-centric care models to enhance treatment accessibility and continuity.
  • Others: Other end users in the personalized cancer medicine market encompass research institutions, academic medical centers, and specialized oncology centers. Trends include collaborative research initiatives, the development of innovative precision oncology platforms, and the integration of artificial intelligence for data-driven insights and therapeutic discoveries.

Report Scope

Feature of the Report Details
Market Size in 2024 USD 347.8 Billion
Projected Market Size in 2033 USD 707.1 Billion
Market Size in 2023 USD 321.4 Billion
CAGR Growth Rate 8.2% CAGR
Base Year 2023
Forecast Period 2024-2033
Key Segment By Type, Application, End User and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Personalized Cancer Medicine Market – Regional Analysis

The Personalized Cancer Medicine Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

  • North America: In North America, a prominent trend in personalized cancer medicine is the widespread adoption of advanced genomic profiling technologies, such as next-generation sequencing (NGS), across academic medical centers and comprehensive cancer centers. Additionally, there is a growing focus on precision oncology research collaborations between academia, industry, and government agencies to drive innovation in targeted therapies and companion diagnostics.
  • Europe: Europe is witnessing a trend towards the development of regulatory frameworks and standards to facilitate the integration of personalized cancer medicine into clinical practice. There is an emphasis on harmonizing reimbursement policies for biomarker testing and targeted therapies across European Union member states, fostering collaboration between healthcare stakeholders, and promoting the use of real-world evidence to inform treatment decisions.
  • Asia-Pacific: In the Asia-Pacific region, a notable trend in personalized cancer medicine is the increasing adoption of telemedicine and digital health solutions to address healthcare disparities, particularly in remote and underserved areas. There is a growing interest in leveraging mobile health technologies, artificial intelligence (AI), and cloud-based platforms to improve access to molecular profiling services, patient education, and treatment monitoring.
  • LAMEA (Latin America, Middle East, and Africa): LAMEA countries are experiencing a trend towards capacity building and infrastructure development to support personalized cancer medicine initiatives. Governments and healthcare organizations are investing in building molecular diagnostics laboratories, training healthcare professionals in genomic medicine, and expanding access to targeted therapies for underserved populations. Additionally, there is a growing focus on public-private partnerships to enhance research collaboration and technology transfer in precision oncology.

Global Personalized Cancer Medicine Market 2024–2033 (By Billion)

www.custommarketinsight.com

Competitive Landscape – Personalized Cancer Medicine Market

The Personalized Cancer Medicine Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:

  • Roche Holding AG
  • Novartis International AG
  • Bristol Myers Squibb Company
  • Merck & Co. Inc.
  • Pfizer Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Johnson & Johnson
  • Illumina Inc.
  • Thermo Fisher Scientific Inc.
  • Qiagen N.V.
  • Foundation Medicine Inc.
  • Guardant Health Inc.
  • Exact Sciences Corporation
  • Agilent Technologies Inc.
  • Others

These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.

New players entering the personalized cancer medicine market are often characterized by their innovative approaches to technology and development. These include startups and biotech firms leveraging advancements in genomics, artificial intelligence, and digital health to offer novel solutions in molecular diagnostics, targeted therapies, and patient engagement.

Meanwhile, key players dominating the market, such as Roche Holding AG, Novartis International AG, and Pfizer Inc., maintain their leadership positions through extensive R&D investments, strategic collaborations, and robust product portfolios.

Their strong presence in the market is further reinforced by established distribution networks, regulatory expertise, and brand recognition, enabling them to effectively navigate the complexities of personalized cancer medicine and maintain a competitive edge.

The Personalized Cancer Medicine Market is segmented as follows:

By Type

  • Personalized Medicine Therapeutics
  • Personalized Medicine Diagnostics

By Application

  • Oncology
  • Infectious disease
  • Neurology or Psychiatry
  • Cardiovascular
  • Others

By End User

  • Hospitals
  • Clinics
  • Others

Regional Coverage:

North America

  • U.S.
  • Canada
  • Mexico
  • Rest of North America

Europe

  • Germany
  • France
  • U.K.
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Taiwan
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Personalized Cancer Medicine Market, (2024 – 2033) (USD Billion)
    • 2.2 Global Personalized Cancer Medicine Market: snapshot
  • Chapter 3. Global Personalized Cancer Medicine Market – Industry Analysis
    • 3.1 Personalized Cancer Medicine Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Advancements in Genomic Technologies
      • 3.2.2 Rising Cancer Incidence and Awareness
      • 3.2.3 Expansion of Targeted Therapies
      • 3.2.4 Healthcare Digitization and Big Data Analytics
      • 3.2.5 Expansion of Immunotherapy.
    • 3.3 Market Restraints
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market Attractiveness Analysis By Type
      • 3.7.2 Market Attractiveness Analysis By Application
      • 3.7.3 Market Attractiveness Analysis By End User
  • Chapter 4. Global Personalized Cancer Medicine Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Personalized Cancer Medicine Market: Company Market Share, 2024
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Personalized Cancer Medicine Market – Type Analysis
    • 5.1 Global Personalized Cancer Medicine Market Overview: By Type
      • 5.1.1 Global Personalized Cancer Medicine Market Share, By Type, 2024 and – 2033
    • 5.2 Personalized Medicine Therapeutics
      • 5.2.1 Global Personalized Cancer Medicine Market by Personalized Medicine Therapeutics, 2024 – 2033 (USD Billion)
    • 5.3 Personalized Medicine Diagnostics
      • 5.3.1 Global Personalized Cancer Medicine Market by Personalized Medicine Diagnostics, 2024 – 2033 (USD Billion)
  • Chapter 6. Global Personalized Cancer Medicine Market – Application Analysis
    • 6.1 Global Personalized Cancer Medicine Market Overview: By Application
      • 6.1.1 Global Personalized Cancer Medicine Market Share, By Application, 2024 and – 2033
    • 6.2 Oncology
      • 6.2.1 Global Personalized Cancer Medicine Market by Oncology, 2024 – 2033 (USD Billion)
    • 6.3 Infectious disease
      • 6.3.1 Global Personalized Cancer Medicine Market by Infectious Disease, 2024 – 2033 (USD Billion)
    • 6.4 Neurology or Psychiatry
      • 6.4.1 Global Personalized Cancer Medicine Market by Neurology or Psychiatry, 2024 – 2033 (USD Billion)
    • 6.5 Cardiovascular
      • 6.5.1 Global Personalized Cancer Medicine Market by Cardiovascular, 2024 – 2033 (USD Billion)
    • 6.6 Others
      • 6.6.1 Global Personalized Cancer Medicine Market by Others, 2024 – 2033 (USD Billion)
  • Chapter 7. Global Personalized Cancer Medicine Market – End User Analysis
    • 7.1 Global Personalized Cancer Medicine Market Overview: By End User
      • 7.1.1 Global Personalized Cancer Medicine Market Share, By End User, 2024 and – 2033
    • 7.2 Hospitals
      • 7.2.1 Global Personalized Cancer Medicine Market by Hospitals, 2024 – 2033 (USD Billion)
    • 7.3 Clinics
      • 7.3.1 Global Personalized Cancer Medicine Market by Clinics, 2024 – 2033 (USD Billion)
    • 7.4 Others
      • 7.4.1 Global Personalized Cancer Medicine Market by Others, 2024 – 2033 (USD Billion)
  • Chapter 8. Personalized Cancer Medicine Market – Regional Analysis
    • 8.1 Global Personalized Cancer Medicine Market Regional Overview
    • 8.2 Global Personalized Cancer Medicine Market Share, by Region, 2024 & – 2033 (USD Billion)
    • 8.3. North America
      • 8.3.1 North America Personalized Cancer Medicine Market, 2024 – 2033 (USD Billion)
        • 8.3.1.1 North America Personalized Cancer Medicine Market, by Country, 2024 – 2033 (USD Billion)
    • 8.4 North America Personalized Cancer Medicine Market, by Type, 2024 – 2033
      • 8.4.1 North America Personalized Cancer Medicine Market, by Type, 2024 – 2033 (USD Billion)
    • 8.5 North America Personalized Cancer Medicine Market, by Application, 2024 – 2033
      • 8.5.1 North America Personalized Cancer Medicine Market, by Application, 2024 – 2033 (USD Billion)
    • 8.6 North America Personalized Cancer Medicine Market, by End User, 2024 – 2033
      • 8.6.1 North America Personalized Cancer Medicine Market, by End User, 2024 – 2033 (USD Billion)
    • 8.7. Europe
      • 8.7.1 Europe Personalized Cancer Medicine Market, 2024 – 2033 (USD Billion)
        • 8.7.1.1 Europe Personalized Cancer Medicine Market, by Country, 2024 – 2033 (USD Billion)
    • 8.8 Europe Personalized Cancer Medicine Market, by Type, 2024 – 2033
      • 8.8.1 Europe Personalized Cancer Medicine Market, by Type, 2024 – 2033 (USD Billion)
    • 8.9 Europe Personalized Cancer Medicine Market, by Application, 2024 – 2033
      • 8.9.1 Europe Personalized Cancer Medicine Market, by Application, 2024 – 2033 (USD Billion)
    • 8.10 Europe Personalized Cancer Medicine Market, by End User, 2024 – 2033
      • 8.10.1 Europe Personalized Cancer Medicine Market, by End User, 2024 – 2033 (USD Billion)
    • 8.11. Asia Pacific
      • 8.11.1 Asia Pacific Personalized Cancer Medicine Market, 2024 – 2033 (USD Billion)
        • 8.11.1.1 Asia Pacific Personalized Cancer Medicine Market, by Country, 2024 – 2033 (USD Billion)
    • 8.12 Asia Pacific Personalized Cancer Medicine Market, by Type, 2024 – 2033
      • 8.12.1 Asia Pacific Personalized Cancer Medicine Market, by Type, 2024 – 2033 (USD Billion)
    • 8.13 Asia Pacific Personalized Cancer Medicine Market, by Application, 2024 – 2033
      • 8.13.1 Asia Pacific Personalized Cancer Medicine Market, by Application, 2024 – 2033 (USD Billion)
    • 8.14 Asia Pacific Personalized Cancer Medicine Market, by End User, 2024 – 2033
      • 8.14.1 Asia Pacific Personalized Cancer Medicine Market, by End User, 2024 – 2033 (USD Billion)
    • 8.15. Latin America
      • 8.15.1 Latin America Personalized Cancer Medicine Market, 2024 – 2033 (USD Billion)
        • 8.15.1.1 Latin America Personalized Cancer Medicine Market, by Country, 2024 – 2033 (USD Billion)
    • 8.16 Latin America Personalized Cancer Medicine Market, by Type, 2024 – 2033
      • 8.16.1 Latin America Personalized Cancer Medicine Market, by Type, 2024 – 2033 (USD Billion)
    • 8.17 Latin America Personalized Cancer Medicine Market, by Application, 2024 – 2033
      • 8.17.1 Latin America Personalized Cancer Medicine Market, by Application, 2024 – 2033 (USD Billion)
    • 8.18 Latin America Personalized Cancer Medicine Market, by End User, 2024 – 2033
      • 8.18.1 Latin America Personalized Cancer Medicine Market, by End User, 2024 – 2033 (USD Billion)
    • 8.19. The Middle-East and Africa
      • 8.19.1 The Middle-East and Africa Personalized Cancer Medicine Market, 2024 – 2033 (USD Billion)
        • 8.19.1.1 The Middle-East and Africa Personalized Cancer Medicine Market, by Country, 2024 – 2033 (USD Billion)
    • 8.20 The Middle-East and Africa Personalized Cancer Medicine Market, by Type, 2024 – 2033
      • 8.20.1 The Middle-East and Africa Personalized Cancer Medicine Market, by Type, 2024 – 2033 (USD Billion)
    • 8.21 The Middle-East and Africa Personalized Cancer Medicine Market, by Application, 2024 – 2033
      • 8.21.1 The Middle-East and Africa Personalized Cancer Medicine Market, by Application, 2024 – 2033 (USD Billion)
    • 8.22 The Middle-East and Africa Personalized Cancer Medicine Market, by End User, 2024 – 2033
      • 8.22.1 The Middle-East and Africa Personalized Cancer Medicine Market, by End User, 2024 – 2033 (USD Billion)
  • Chapter 9. Company Profiles
    • 9.1 Roche Holding AG
      • 9.1.1 Overview
      • 9.1.2 Financials
      • 9.1.3 Product Portfolio
      • 9.1.4 Business Strategy
      • 9.1.5 Recent Developments
    • 9.2 Novartis International AG
      • 9.2.1 Overview
      • 9.2.2 Financials
      • 9.2.3 Product Portfolio
      • 9.2.4 Business Strategy
      • 9.2.5 Recent Developments
    • 9.3 Bristol Myers Squibb Company
      • 9.3.1 Overview
      • 9.3.2 Financials
      • 9.3.3 Product Portfolio
      • 9.3.4 Business Strategy
      • 9.3.5 Recent Developments
    • 9.4 Merck & Co. Inc.
      • 9.4.1 Overview
      • 9.4.2 Financials
      • 9.4.3 Product Portfolio
      • 9.4.4 Business Strategy
      • 9.4.5 Recent Developments
    • 9.5 Pfizer Inc.
      • 9.5.1 Overview
      • 9.5.2 Financials
      • 9.5.3 Product Portfolio
      • 9.5.4 Business Strategy
      • 9.5.5 Recent Developments
    • 9.6 AstraZeneca PLC
      • 9.6.1 Overview
      • 9.6.2 Financials
      • 9.6.3 Product Portfolio
      • 9.6.4 Business Strategy
      • 9.6.5 Recent Developments
    • 9.7 Bayer AG
      • 9.7.1 Overview
      • 9.7.2 Financials
      • 9.7.3 Product Portfolio
      • 9.7.4 Business Strategy
      • 9.7.5 Recent Developments
    • 9.8 Johnson & Johnson
      • 9.8.1 Overview
      • 9.8.2 Financials
      • 9.8.3 Product Portfolio
      • 9.8.4 Business Strategy
      • 9.8.5 Recent Developments
    • 9.9 Illumina Inc.
      • 9.9.1 Overview
      • 9.9.2 Financials
      • 9.9.3 Product Portfolio
      • 9.9.4 Business Strategy
      • 9.9.5 Recent Developments
    • 9.10 Thermo Fisher Scientific Inc.
      • 9.10.1 Overview
      • 9.10.2 Financials
      • 9.10.3 Product Portfolio
      • 9.10.4 Business Strategy
      • 9.10.5 Recent Developments
    • 9.11 Qiagen N.V.
      • 9.11.1 Overview
      • 9.11.2 Financials
      • 9.11.3 Product Portfolio
      • 9.11.4 Business Strategy
      • 9.11.5 Recent Developments
    • 9.12 Foundation Medicine Inc.
      • 9.12.1 Overview
      • 9.12.2 Financials
      • 9.12.3 Product Portfolio
      • 9.12.4 Business Strategy
      • 9.12.5 Recent Developments
    • 9.13 Guardant Health Inc.
      • 9.13.1 Overview
      • 9.13.2 Financials
      • 9.13.3 Product Portfolio
      • 9.13.4 Business Strategy
      • 9.13.5 Recent Developments
    • 9.14 Exact Sciences Corporation
      • 9.14.1 Overview
      • 9.14.2 Financials
      • 9.14.3 Product Portfolio
      • 9.14.4 Business Strategy
      • 9.14.5 Recent Developments
    • 9.15 Agilent Technologies Inc.
      • 9.15.1 Overview
      • 9.15.2 Financials
      • 9.15.3 Product Portfolio
      • 9.15.4 Business Strategy
      • 9.15.5 Recent Developments
    • 9.16 Others.
      • 9.16.1 Overview
      • 9.16.2 Financials
      • 9.16.3 Product Portfolio
      • 9.16.4 Business Strategy
      • 9.16.5 Recent Developments
List Of Figures

Figures No 1 to 26

List Of Tables

Tables No 1 to 77

Report Methodology

In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:

Preliminary Data Mining

On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.

Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.

Statistical Model

Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.

Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.

Some of the variables taken into account for forecasting are as follows:

• Industry drivers and constraints, as well as their current and projected impact

• The raw material case, as well as supply-versus-price trends

• Current volume and projected volume growth through 2032

We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.

Primary Validation

This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.

Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.

All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:

• Market leaders

• Suppliers of raw materials

• Suppliers of raw materials

• Buyers.

The following are the primary research objectives:

• To ensure the accuracy and acceptability of our data.

• Gaining an understanding of the current market and future projections.

Data Collection Matrix

Perspective Primary research Secondary research
Supply-side
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data
Demand-side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers


Market Analysis Matrix

Qualitative analysis Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2032
  • Market revenue estimates and forecasts up to 2032, by technology
  • Market revenue estimates and forecasts up to 2032, by application
  • Market revenue estimates and forecasts up to 2032, by type
  • Market revenue estimates and forecasts up to 2032, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Prominent Player

  • Roche Holding AG
  • Novartis International AG
  • Bristol Myers Squibb Company
  • Merck & Co. Inc.
  • Pfizer Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Johnson & Johnson
  • Illumina Inc.
  • Thermo Fisher Scientific Inc.
  • Qiagen N.V.
  • Foundation Medicine Inc.
  • Guardant Health Inc.
  • Exact Sciences Corporation
  • Agilent Technologies Inc.
  • Others

FAQs

The key factors driving the Market are Advancements in Genomic Technologies, Rising Cancer Incidence and Awareness, Expansion of Targeted Therapies, Healthcare Digitization and Big Data Analytics And Expansion of Immunotherapy.

The “Oncology” had the largest share in the global market for Personalized Cancer Medicine.

The “Personalized Medicine Therapeutics” category dominated the market in 2023.

The key players in the market are Roche Holding AG, Novartis International AG, Bristol Myers Squibb Company, Merck & Co. Inc., Pfizer Inc., AstraZeneca PLC, Bayer AG, Johnson & Johnson, Illumina Inc., Thermo Fisher Scientific Inc., Qiagen N.V., Foundation Medicine Inc., Guardant Health Inc., Exact Sciences Corporation, Agilent Technologies Inc., Others.

“North America” had the largest share in the Personalized Cancer Medicine Market.

The global market is projected to grow at a CAGR of 8.2% during the forecast period, 2024-2033.

The Personalized Cancer Medicine Market size was valued at USD 347.8 Billion in 2024.

PURCHASE OPTIONS

$

3990


$

4990


$

5990


$

2290


$

2390

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • Free 25% or 40 hours of customisation.
  • Free post-sale service assistance.
  • 15% discount on your next purchase.
  • Dedicated account Associate .
  • Permission to print the report.
  • Service guarantee available.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • Free 35% or 60 hours of customisation.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantee available.
  • Personalised market brief by author.
  • Permission to print the report.
  • Report in your Language.
  • PDF, Excel and Power Point.
  • Can be accessible by unlimited users.
  • Free 40% or 80 hours of customisation.
  • Free post-sale service assistance.
  • 30% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account manager.
  • Service guarantee available.
  • Report in your Language.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
  • 15% discount on your next purchase.
  • Free 20% or 10 hours of customisation.
  • In-Depth Company Profiles.
  • SWOT Analysis.
  • Identify your Competitors.
  • Recent Development Analysis.
  • Competitor Pricing Strategies.
  • Competitor Marketing Strategies.
  • Competitor Positioning and Messaging.
  • Competitor Product’s Strengths.
  • Free 20% or 10 Hours of Customisation.
  • 15% Discount on your Next Purchase.
  • Upgradable to other licenses.
  • PDF Format.
  • Permission to Print the Report.

Want to customize this report?
100% FREE CUSTOMIZATION!